191 related articles for article (PubMed ID: 33637589)
1. Semiautomatic Tumor Delineation for Evaluation of
Carlsen EA; Johnbeck CB; Loft M; Pfeifer A; Oturai P; Langer SW; Knigge U; Ladefoged CN; Kjaer A
J Nucl Med; 2021 Nov; 62(11):1564-1570. PubMed ID: 33637589
[TBL] [Abstract][Full Text] [Related]
2.
Carlsen EA; Johnbeck CB; Binderup T; Loft M; Pfeifer A; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Knigge U; Kjaer A
J Nucl Med; 2020 Oct; 61(10):1491-1497. PubMed ID: 32111685
[TBL] [Abstract][Full Text] [Related]
3. Quantitative
Ortega C; Wong RKS; Schaefferkoetter J; Veit-Haibach P; Myrehaug S; Juergens R; Laidley D; Anconina R; Liu A; Metser U
J Nucl Med; 2021 Oct; 62(10):1406-1414. PubMed ID: 33579805
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
5. Visual and whole-body quantitative analyses of
Hotta M; Sonni I; Thin P; Nguyen K; Gardner L; Ciuca L; Hayrapetian A; Lewis M; Lubin D; Allen-Auerbach M
Ann Nucl Med; 2024 Apr; 38(4):296-304. PubMed ID: 38252228
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of somatostatin receptor expressing tumor volume calculated from
Toriihara A; Baratto L; Nobashi T; Park S; Hatami N; Davidzon G; Kunz PL; Iagaru A
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2244-2251. PubMed ID: 31350603
[TBL] [Abstract][Full Text] [Related]
7. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
8.
Loft M; Carlsen EA; Johnbeck CB; Johannesen HH; Binderup T; Pfeifer A; Mortensen J; Oturai P; Loft A; Berthelsen AK; Langer SW; Knigge U; Kjaer A
J Nucl Med; 2021 Jan; 62(1):73-80. PubMed ID: 32444370
[No Abstract] [Full Text] [Related]
9. Prediction of
Lee H; Kipnis ST; Niman R; O'Brien SR; Eads JR; Katona BW; Pryma DA
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201627
[TBL] [Abstract][Full Text] [Related]
10.
Lee H; Eads JR; Pryma DA
Oncologist; 2021 Jan; 26(1):21-29. PubMed ID: 32886441
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of
Parghane RV; Naik C; Talole S; Desmukh A; Chaukar D; Banerjee S; Basu S
Head Neck; 2020 Mar; 42(3):401-416. PubMed ID: 31755622
[TBL] [Abstract][Full Text] [Related]
12. The Correlation Between [
Yu J; Li N; Li J; Lu M; Leal JP; Tan H; Su H; Fan Y; Zhang Y; Zhao W; Zhu H; Pomper MG; Zhou Y; Yang Z
Mol Imaging Biol; 2019 Oct; 21(5):984-990. PubMed ID: 30796708
[TBL] [Abstract][Full Text] [Related]
13. Correlation and Comparison of Somatostatin Receptor Type 2 Immunohistochemical Scoring Systems with 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.
Yu J; Cao F; Zhao X; Xie Q; Lu M; Li J; Yang Z; Sun Y
Neuroendocrinology; 2022; 112(4):358-369. PubMed ID: 34077939
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine liver metastases treated using transarterial radioembolization: Identification of prognostic parameters at 68Ga-DOTATATE PET/CT.
Ingenerf M; Grawe F; Winkelmann M; Karim H; Ruebenthaler J; Fabritius MP; Ricke J; Seidensticker R; Auernhammer CJ; Zacherl MJ; Seidensticker M; Schmid-Tannwald C
Diagn Interv Imaging; 2024 Jan; 105(1):15-25. PubMed ID: 37453859
[TBL] [Abstract][Full Text] [Related]
15. Radiomics-Based Texture Analysis of
Atkinson C; Ganeshan B; Endozo R; Wan S; Aldridge MD; Groves AM; Bomanji JB; Gaze MN
Front Oncol; 2021; 11():686235. PubMed ID: 34408979
[TBL] [Abstract][Full Text] [Related]
16. The prognostic role of whole-body volumetric 68 GA-DOTATATE PET/computed tomography parameters in patients with gastroenteropancreatic neuroendocrine tumor treated with 177 LU-DOTATATE.
Kepenek F; Kömek H; Can C; Kaplan İ; Altindağ S; Gündoğan C
Nucl Med Commun; 2023 Jun; 44(6):509-517. PubMed ID: 37038931
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of
Zidan L; Iravani A; Oleinikov K; Ben-Haim S; Gross DJ; Meirovitz A; Maimon O; Akhurst T; Michael M; Hicks RJ; Grozinsky-Glasberg S; Kong G
J Nucl Med; 2022 Feb; 63(2):218-225. PubMed ID: 34049983
[TBL] [Abstract][Full Text] [Related]
18. Standardized uptake values and ratios on 68Ga-DOTATATE PET-computed tomography for normal organs and malignant lesions and their correlation with Krenning score in patients with metastatic neuroendocrine tumors.
Menon BK; Kalshetty A; Bhattacharjee A; Basu S
Nucl Med Commun; 2020 Oct; 41(10):1095-1099. PubMed ID: 32732598
[TBL] [Abstract][Full Text] [Related]
19. Activity Dose Reduction in
Loft M; Carlsen EA; Johnbeck CB; Jensen CV; Andersen FL; Langer SW; Oturai P; Knigge U; Kjaer A
Mol Imaging Biol; 2022 Aug; 24(4):600-611. PubMed ID: 35167028
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
